About Ironshore Pharmaceuticals
Ironshore Pharmaceuticals is a Healthcare company based in George Town (Cayman Islands) founded in 2008, and was acquired by Collegium Pharma in July 2024. Drug delivery technology and ADHD therapeutics are developed. Ironshore Pharmaceuticals offers products and services including Medications Portfolio. Its focus areas include Life Sciences, Neurology, Drugs and Neurodevelopmental Disorders. Its legal entity is IRONSHORE PHARMACEUTICALS INC.
Company details
Ironshore Pharmaceuticals was founded in 2008 in George Town, Cayman Islands, within the pharmaceuticals sector. Drug delivery technology and treatments for attention deficit hyperactivity disorder are developed, with proprietary Delexis utilized for controlled drug release during ingestion and absorption. Operations focus on central nervous system stimulants, including the flagship prescription medicine JORNAY PM for ADHD management. Activities center on therapeutic innovation in this niche area.
- Headquarters George Town, Cayman Islands
- Stage Acquired
- SectorsHealthcare
- Website ironshorepharma.com
- Social LinkedIn X Facebook
- Acquired by Collegium Pharma (Jul 2024)
- Legal Name Ironshore Pharmaceuticals Inc.
- Latest Funding Round$143M (USD), Debt – Conventional
Aug 2018
- InvestorsMorgan Stanley
& 1 more
- Acquired byCollegium Pharma
(Jul 2024)
Products & Services of Ironshore Pharmaceuticals
Ironshore Pharmaceuticals offers a comprehensive portfolio of products and services, including Medications Portfolio.
Treatments for serious medical conditions through scientific development
Funding Insights of Ironshore Pharmaceuticals
- Total Rounds 2
- Last Round Debt – Conventional — $143M
- First Round $200M
(Jan 2017)
- Investors Count 1
All 2 funding rounds of Ironshore Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2018 | $143M | Debt – Conventional | – | – | – |
| Jan 2017 | $200M | Debt – Conventional | – | – |
2 investors in total: 2 institutional.
Investors in Ironshore Pharmaceuticals
Ironshore Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Morgan Stanley and Collegium Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Wealth management, investment advisory, and financial services are provided. | 1935 | morganstanley.com | New York, United States | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | collegiumpharma.com | Canton, United States |
Investor details for Ironshore Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ironshore Pharmaceuticals
4 people are tracked at Ironshore Pharmaceuticals (3 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Danny Villeneuve | Chief Commercial Officer | Leadership |
Bev Incledon | Chief Scientific Officer | Leadership |
Nelson Isabel | CFO | Leadership |
Kevin Bain | Director | Board & advisors |
Complete people profiles for Ironshore Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ironshore Pharmaceuticals
4 dated milestones of Ironshore Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Ironshore Pharmaceuticals is founded.
- Funding First funding round of $200.0M.
- Funding Latest funding round, Debt – Conventional, of $143.0M.
- Exit Acquired by Collegium Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ironshore Pharmaceuticals
Complete news archive for Ironshore Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ironshore Pharmaceuticals
Ironshore Pharmaceuticals was founded in 2008 and raised its 1st funding round 9 years after it was founded.
Ironshore Pharmaceuticals is headquartered in George Town, Cayman Islands.
Ironshore Pharmaceuticals was founded in 2008 in George Town, Cayman Islands, within the pharmaceuticals sector. Drug delivery technology and treatments for attention deficit hyperactivity disorder are developed, with proprietary Delexis utilized for controlled drug release during ingestion and absorption. Operations focus on central nervous system stimulants, including the flagship prescription medicine JORNAY PM for ADHD management. Activities center on therapeutic innovation in this niche area.
Ironshore Pharmaceuticals offers Medications Portfolio.
Ironshore Pharmaceuticals has 2 investors. Key investors include Morgan Stanley, and Collegium Pharma.
Ironshore Pharmaceuticals operates through Ironshore Pharmaceuticals Inc..
Yes. Ironshore Pharmaceuticals was acquired by Collegium Pharma in July 2024.